Wedoany.com Report-Aug. 15, Sartorius Stedim Biotech, based in Aubagne, France, has formed a strategic partnership with Nanotein Technologies, a company specializing in advanced immune cell activation reagents. As part of this collaboration, Sartorius will invest up to $3 million in a minority stake in Nanotein to support the commercialization and co-development of products leveraging Nanotein’s NanoSpark® platform.

Through an exclusive distribution agreement, Sartorius will globally distribute Nanotein’s flagship products: the NanoSpark® STEM-T Soluble T Cell Activator and the NanoSpark® GROW-NK Soluble Activator. These reagents are engineered to boost the expansion and quality of T cells and natural killer (NK) cells, critical components in cell therapies such as CAR-T and NK-based cancer treatments.

The production of effective cell therapies relies on activating immune cells to achieve robust expansion and high-quality cell yields. Developers often encounter challenges, including dependence on feeder cells and variable outcomes. Curtis Hodge, Co-Founder and CEO of Nanotein Technologies, stated: “Nanotein’s soluble activators are designed to improve cell therapy expansion by enhancing the quality and quantity of T cells and providing a feeder-free soluble activator for NK cell activation and expansion, addressing critical challenges in the manufacturing process.”

The partnership aims to streamline cell therapy manufacturing processes. René Fáber, CEO of Sartorius Stedim Biotech, said: “This partnership will provide our customers with access to some of the most promising new tools for simplifying workflows and thus improving immune cell manufacturing. Together with Nanotein, we’re enabling cell therapy manufacturers to innovate with greater speed and confidence – from early process development to the clinic.”

Additionally, Sartorius and Nanotein will collaborate on the NanoSpark® platform to create innovative product offerings tailored to the growing cell and gene therapy markets. This partnership enhances access to advanced tools, supporting the development of efficient and reliable cell therapies worldwide.

By combining Sartorius’s expertise in biotech solutions with Nanotein’s cutting-edge technology, the collaboration is poised to address key industry challenges, improve manufacturing efficiency, and accelerate the delivery of next-generation therapies to patients.